The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1024
ISSUE1024
April 10, 1998
Toremifene and Letrozole for Advanced Breast Cancer
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Toremifene and Letrozole for Advanced Breast Cancer
April 10, 1998 (Issue: 1024)
The antiestrogen toremifene (Fareston - Schering) and the selective aromatase inhibitor letrozole (Femara - Novartis) have been approved by the FDA for treatment of advanced breast cancer in postmenopausal women.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.